Redirecting to https://www.morningstar.com/news/business-wire/20260604968959/phase-iii-findckd-results-show-bayers-kerendia-finerenone-improved-egfr-slope-and-reduced-risk-of-a-composite-kidney-cardiovascular-outcome-in-adults-with-nondiabetic-chronic-kidney-disease